Zymar (soln)

Zymar (soln)

Generic: gatifloxacin 0.3%

Zymaxid (soln)
DOSAGE Conjunctivitis: Day 1: 1 gtt q2hrs while awake (up to 8 times), Day 2-7: 1 gtt BID-QID while awake
Bacterial Keratitis
Low risk of vision loss: 1 gtts q1-2hr + Optional add on tobramycin or ciprofloxacin ung qHS
Moderate risk of vision loss: Loading dosage q5min for 5 doses, then q30min until midnight, then q1hr
Vision-threatening: Consider fortified tobraymycin or gentamicin (15 mg/ml) q1hr, alternating with fortified cefazolin (50mg/ML) or vancomycin (25mg/mL) q1hr.
GENERIC gatifloxacin 0.3%
SIZE 5mL
INDICATIONS ZYMAXID® is indicated for the treatment of bacterial conjunctivitis, off label for corneal ulcer.
MECHANISM OF ACTION fluoroquinolone (4th): Binds bacterial DNA gyrase topoisomerase II and topoisomerase IV
MICROBIOLOGY Active against a very broad range of gram negative and positive Organisms. Gatifloxacin has been shown to be active against most isolates of the following organisms both microbiologically and clinically, in conjunctival infections: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group* Streptococcus oralis* Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae
CONTRAINDICATIONS & WARNINGS Zymar is contraindicated in patients with a history of hypersensitivity to gatifloxacin, to other quinolones, or to any of the components in this medication
PEDIATRIC USE It is not known if Zymar is safe and effective in children younger than 1 year of age
PREGNANCY Category C: There are no available data on the use of ZYMAXID® in pregnant women to inform a drug-associated risk. Administration of oral gatifloxacin to pregnant rats and rabbits throughout organogenesis did not produce adverse development outcomes at clinically relevant doses. Administration of gatifloxacin to rats during late gestation through lactation did not produce adverse maternal, fetal or neonatal effects at clinically relevant doses.
NOTE BAK preserved.